{"id":675546,"date":"2026-01-05T14:14:13","date_gmt":"2026-01-05T14:14:13","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/675546\/"},"modified":"2026-01-05T14:14:13","modified_gmt":"2026-01-05T14:14:13","slug":"from-weight-loss-injections-to-pills-wegovy-goes-oral-for-us-users-starting-at-us149","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/675546\/","title":{"rendered":"From weight-loss injections to pills: Wegovy goes oral for US users, starting at US$149"},"content":{"rendered":"\n<p>COPENHAGEN, Jan 5 \u2014 Denmark\u2019s Novo Nordisk will offer its 1.5 and 4 \u200dmilligram Wegovy weightloss pills at US$149 (about RM685) per month \u200cto self-paying patients in the United States from January 5, it said on \u200dMonday.<\/p>\n<p>It will from the same date offer the highest doses of the drug pill, of 9 and 25 milligram, at US$299 (about RM1,217) per month, it said on its website.<\/p>\n<p>The price for the 4 milligram dose will \u200drise \u200dto US$199 (about RM810) per month from April 15, it said.<\/p>\n<p>The US Food and \u200bDrug Administration on December 22 approved the pill, giving Novo Nordisk a leg up as it looks to regain lost ground from rival \u200cEli Lilly.<\/p>\n<p>The semaglutide pills contain the same active ingredient as injectable Wegovy \u200dand Ozempic, and will be \u200csold \u200dunder the brand name Wegovy.\u00a0<\/p>\n<p>Novo Nordisk \u200dalready sells an oral semaglutide for \u200dtype 2 diabetes, Rybelsus. \u2014 Reuters<\/p>\n","protected":false},"excerpt":{"rendered":"COPENHAGEN, Jan 5 \u2014 Denmark\u2019s Novo Nordisk will offer its 1.5 and 4 \u200dmilligram Wegovy weightloss pills at&hellip;\n","protected":false},"author":2,"featured_media":675547,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4315],"tags":[105,4326,205375,205379,205378,2752,16,15,205377,205376],"class_list":{"0":"post-675546","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-health","9":"tag-medication","10":"tag-novo-nordisk-wegovy","11":"tag-rybelsus","12":"tag-semaglutide-pills","13":"tag-type-2-diabetes","14":"tag-uk","15":"tag-united-kingdom","16":"tag-us-food-and-drug-administration","17":"tag-wegovy-weightloss-pills"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/115842912523949135","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/675546","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=675546"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/675546\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/675547"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=675546"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=675546"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=675546"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}